Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04624113
Title Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Washington University School of Medicine
Indications

hypopharynx cancer

oral squamous cell carcinoma

oropharynx cancer

head and neck cancer

head and neck squamous cell carcinoma

laryngeal squamous cell carcinoma

Therapies

Pembrolizumab + Tazemetostat

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.